HealthInvest Partners AB Has $1.02 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

HealthInvest Partners AB raised its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 191.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 538,621 shares of the company’s stock after acquiring an additional 353,721 shares during the quarter. HealthInvest Partners AB owned about 0.44% of Mersana Therapeutics worth $1,018,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. US Bancorp DE bought a new stake in Mersana Therapeutics in the third quarter worth $31,000. Russell Investments Group Ltd. raised its stake in shares of Mersana Therapeutics by 976.7% in the 1st quarter. Russell Investments Group Ltd. now owns 9,453 shares of the company’s stock valued at $42,000 after acquiring an additional 8,575 shares in the last quarter. Intech Investment Management LLC bought a new stake in Mersana Therapeutics during the third quarter worth approximately $52,000. Algert Global LLC bought a new position in Mersana Therapeutics in the 2nd quarter worth $90,000. Finally, Walleye Trading LLC bought a new stake in Mersana Therapeutics during the 1st quarter valued at approximately $141,000. 93.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MRSN shares. Lifesci Capital raised Mersana Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th. Robert W. Baird lowered their price objective on Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Finally, Citigroup assumed coverage on shares of Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Insider Buying and Selling at Mersana Therapeutics

In related news, CEO Martin H. Jr. Huber sold 50,423 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $1.76, for a total value of $88,744.48. Following the sale, the chief executive officer now directly owns 116,327 shares in the company, valued at $204,735.52. This trade represents a 30.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders sold 70,849 shares of company stock worth $129,184. Insiders own 11.80% of the company’s stock.

Mersana Therapeutics Stock Down 1.8 %

Shares of MRSN stock traded down $0.04 on Thursday, reaching $2.18. 10,549 shares of the stock were exchanged, compared to its average volume of 1,600,207. The stock has a 50 day moving average price of $2.07 and a 200 day moving average price of $2.03. Mersana Therapeutics, Inc. has a one year low of $1.22 and a one year high of $6.28. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $12.60 million for the quarter, compared to analyst estimates of $7.53 million. During the same quarter last year, the firm earned ($0.35) EPS. The company’s revenue for the quarter was up 63.6% on a year-over-year basis. On average, sell-side analysts anticipate that Mersana Therapeutics, Inc. will post -0.64 earnings per share for the current fiscal year.

Mersana Therapeutics Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.